Abstract 184P
Background
The Lung Cancer Policy Network, a global multi-stakeholder initiative of experts in lung cancer, has developed a framework to inform implementation of LDCT screening. The framework and associated online toolkit aim to support those involved in the planning and delivery of LDCT screening programmes around the world.
Methods
System readiness refers to the ability of health systems to rapidly and sustainably adapt policies, processes and infrastructure to support the integration of new components of care. Assessing health system readiness is therefore an important step when planning the implementation of screening programmes. With this understanding, a bespoke framework to assess readiness for implementation of LDCT screening was developed. The framework was informed by a review of existing peer-reviewed and grey literature from 2010–22, expert interviews and insights from Network members. The framework was further refined after it was applied to five countries where screening implementation is underway: Canada, Poland, South Korea, the UK and the US.
Results
The implementation framework and online toolkit were made publicly available in March 2023. To date, the framework has been downloaded over 800 times and the toolkit has been used by almost 1,500 people. The framework will help with assessing health system readiness for screening implementation at a national or regional level. The framework is organised into six domains, each consisting of metrics to identify gaps in screening requirements (including local infrastructure, technical and workforce capacity, governance, data flows and existing care pathways), and measures to address these. Researchers and decision-makers can plan and resource their screening programmes by using this information and the supporting material in the online toolkit.
Conclusions
To our knowledge, this is the first framework to support implementation of LDCT screening programmes globally. Application of the framework to a given health system can provide evidence to inform policy considerations for implementation, facilitating high-quality, equitable and cost-effective screening.
Legal entity responsible for the study
The Health Policy Partnership.
Funding
The Health Policy Partnership provides Secretariat duties for the Lung Cancer Policy Network, which received funding from AstraZeneca, Guardant, Medtronic, Johnson & Johnson,Merck, Sharpe & Dohme (MSD) and Siemens Healthineers for the research that and development of the implementation framework which is described in this abstract.
Disclosure
H. Wilcox: Financial Interests, Personal, Full or part-time Employment, The Health Policy Partnership (the organization where Helena Wilcox is employed) provides Secretariat duties for the Lung Cancer Policy Network, which received funding from AstraZeneca, Guardant, Medtronic, Johnson & Johnson, Merck, Sharpe & Dohme (MSD) and Siemens Healthineers for the research that and development of the implementation framework which is described in this abstract. Helena Wilcox has not received any direct consultancy fees for any of this work. The Health Policy Partnership; Financial Interests, Institutional, Full or part-time Employment, The Health Policy Partnership has been commissioned over the past 24 months to conduct non-promotional, non-product related policy projects for: Advanced Accelerator Applications, AEPHCPO (Novartis UAE), Alexion, All.Can International, Amazon Web Services, Amgen, Arythmia Alliance, AstraZeneca, Batten Disease Family Association, Bayer, Bristol Myers Squibb (BMS), Boehringer Ingelheim European Federation of Pharmaceutical Industries and Associations (EFPIA), Elekta, European Society of Anaesthesiology and Intensive Care (ESAIC), GSK, Global Heart Hub (GHH), Guardant Health, Indivior, Initiative Herzklappe e.V, International Cardiomyopathy Network Janssen Pharmaceutica NV, Johnson & Johnson, Life Technologies Europe BV, Medicines for Europe, Medtronic, Merck Sharpe & Dohme (MSD), Neuroendocrine Cancer UK, National Institute for Prevention and Cardiovascular Health (NIPC), Novartis, Novo Nordisk, Philips, Roche Diagnostics, Sanofi, Sophia Genetics, Stemline Therapeutics, Stockholm Institute: The Health Policy Partnership; Non-Financial Interests, Personal, Member: The International Association for the Study of Lung Cancer. E. Wheeler: Financial Interests, Personal, Invited Speaker, The Health Policy Partnership (the organization where Eleanor Wheeler is employed) provides Secretariat duties for the Lung Cancer Policy Network, which received funding from AstraZeneca, Guardant, Medtronic, Johnson & Johnson, Merck, Sharpe & Dohme (MSD) and Siemens Healthineers for the research that and development of the implementation framework which is described in this abstract. Eleanor Wheeler has not received any direct consultancy fees for any of this work.: The Health Policy Partnership; Financial Interests, Institutional, Full or part-time Employment, The Health Policy Partnership has been commissioned over the past 24 months to conduct non-promotional, non-product related policy projects for: Advanced Accelerator Applications, AEPHCPO (Novartis UAE), Alexion, All.Can International, Amazon Web Services, Amgen, Arythmia Alliance, AstraZeneca, Batten Disease Family Association, Bayer, Bristol Myers Squibb (BMS), Boehringer Ingelheim European Federation of Pharmaceutical Industries and Associations (EFPIA), Elekta, European Society of Anaesthesiology and Intensive Care (ESAIC), GSK, Global Heart Hub (GHH), Guardant Health, Indivior, Initiative Herzklappe e.V, International Cardiomyopathy Network Janssen Pharmaceutica NV, Johnson & Johnson, Life Technologies Europe BV, Medicines for Europe, Medtronic, Merck Sharpe & Dohme (MSD), Neuroendocrine Cancer UK, National Institute for Prevention and Cardiovascular Health (NIPC), Novartis, Novo Nordisk, Philips, Roche Diagnostics, Sanofi, Sophia Genetics, Stemline Therapeutics, Stockholm Institute: The Health Policy Partnership; Non-Financial Interests, Personal, Member: The International Association for the Study of Lung Cancer (IASLC). S. Wait: Financial Interests, Personal, Full or part-time Employment, The Health Policy Partnership (the organization where Suzanne Wait is employed) provides Secretariat duties for the Lung Cancer Policy Network, which received funding from AstraZeneca, Guardant, Medtronic, Johnson & Johnson and Merck, Sharpe & Dohme (MSD), and Siemens Healthineers for the research that and development of the implementation framework which is described in this abstract. Suzanne Wait has not received any direct consultancy fees for any of this work.: The Health Policy Partnership; Financial Interests, Personal, Invited Speaker, The Health Policy Partnership (the organization where Suzanne Wait is employed) provides Secretariat duties for the Lung Cancer Policy Network, which received funding from AstraZeneca, Guardant, Medtronic, Johnson & Johnson and Merck, Sharpe & Dohme (MSD), and Siemens Healthineers for the research that and development of the implementation framework which is described in this abstract. Suzanne Wait has not received any direct consultancy fees for any of this work.: The Health Policy Partnership; Non-Financial Interests, Personal, Member, Active member since 2016: The European Society of Medical Oncology; Financial Interests, Institutional, Invited Speaker, AEPHCPO (Novartis UAE), Alexion, All.Can International, Amazon Web Services, Amgen, Arythmia Alliance, AstraZeneca, Batten Disease Family Association, Bayer, Bristol Myers Squibb (BMS), Boehringer Ingelheim European Federation of Pharmaceutical Industries and Associations (EFPIA), Elekta, European Society of Anaesthesiology and Intensive Care (ESAIC), GSK, Global Heart Hub (GHH), Guardant Health, Indivior, Initiative Herzklappe e.V, International Cardiomyopathy Network Janssen Pharmaceutica NV, Johnson & Johnson, Life Technologies Europe BV, Medicines for Europe, Medtronic, Merck Sharpe & Dohme (MSD), Neuroendocrine Cancer UK, National Institute for Prevention and Cardiovascular Health (NIPC), Novartis, Novo Nordisk, Philips, Roche Diagnostics, Sanofi, Sophia Genetics, Stemline Therapeutics, Stockholm Institute for Research (SIR) UCB Biopharma, Vifor Pharma, and Vision Zero Cancer.: The Health Policy Partnership; Financial Interests, Personal, Ownership Interest, Suzanne Wait has an owership interest in The Health Policy Partnership which provides Secretariat duties for the Lung Cancer Policy Network, which received funding from AstraZeneca, Guardant, Medtronic, Johnson & Johnson and Merck, Sharpe & Dohme (MSD), and Siemens Healthineers for the research that and development of the implementation framework which is described in this abstract.: The Health Policy Partnership. D. Bancroft: Financial Interests, Personal, Full or part-time Employment, The Health Policy Partnership (the organization where Dani Bancroft was employed) provides Secretariat duties for the Lung Cancer Policy Network, which received funding from AstraZeneca, Guardant, Medtronic, Johnson & Johnson,Merck, Sharpe & Dohme (MSD) and Siemens Healthineers for the research that and development of the implementation framework which is described in this abstract. Dani Bancroft did not received any direct consultancy fees for any of this work.: The Health Policy Partnership; Financial Interests, Institutional, Funding, The Health Policy Partnership has been commissioned over the past 24 months to conduct non-promotional, non-product related policy projects for: Advanced Accelerator Applications, AEPHCPO (Novartis UAE), Alexion, All.Can International, Amazon Web Services, Amgen, Arythmia Alliance, AstraZeneca, Batten Disease Family Association, Bayer, Bristol Myers Squibb (BMS), Boehringer Ingelheim European Federation of Pharmaceutical Industries and Associations (EFPIA), Elekta, European Society of Anaesthesiology and Intensive Care (ESAIC), GSK, Global Heart Hub (GHH), Guardant Health, Indivior, Initiative Herzklappe e.V, International Cardiomyopathy Network Janssen Pharmaceutica NV, Johnson & Johnson, Life Technologies Europe BV, Medicines for Europe, Medtronic, Merck Sharpe & Dohme (MSD), Neuroendocrine Cancer UK, National Institute for Prevention and Cardiovascular Health (NIPC), Novartis, Novo Nordisk, Philips, Roche Diagnostics, Sanofi, Sophia Genetics, Stemline Therapeutics, Stockholm Institute: The Health Policy Partnership. J. Hooper: Financial Interests, Personal, Full or part-time Employment, The Health Policy Partnership (the organization where Jessica Hooper is employed) provides Secretariat duties for the Lung Cancer Policy Network, which received funding from AstraZeneca, Guardant, Medtronic, Johnson & Johnson, Merck, Sharpe & Dohme (MSD) and Siemens Healthineers for the research that and development of the implementation framework which is described in this abstract. Jessica Hooper has not received any direct consultancy fees for any of this work.: The Health Policy Partnership; Financial Interests, Institutional, Full or part-time Employment, The Health Policy Partnership has been commissioned over the past 24 months to conduct non-promotional, non-product related policy projects for: Advanced Accelerator Applications, AEPHCPO (Novartis UAE), Alexion, All.Can International, Amazon Web Services, Amgen, Arythmia Alliance, AstraZeneca, Batten Disease Family Association, Bayer, Bristol Myers Squibb (BMS), Boehringer Ingelheim European Federation of Pharmaceutical Industries and Associations (EFPIA), Elekta, European Society of Anaesthesiology and Intensive Care (ESAIC), GSK, Global Heart Hub (GHH), Guardant Health, Indivior, Initiative Herzklappe e.V, International Cardiomyopathy Network Janssen Pharmaceutica NV, Johnson & Johnson, Life Technologies Europe BV, Medicines for Europe, Medtronic, Merck Sharpe & Dohme (MSD), Neuroendocrine Cancer UK, National Institute for Prevention and Cardiovascular Health (NIPC), Novartis, Novo Nordisk, Philips, Roche Diagnostics, Sanofi, Sophia Genetics, Stemline Therapeutics, Stockholm Institute f: The Health Policy Partnership. C. Melson: Financial Interests, Personal, Full or part-time Employment, The Health Policy Partnership (the organization where Chris Melson is employed) provides Secretariat duties for the Lung Cancer Policy Network, which received funding from AstraZeneca, Guardant, Medtronic, Johnson & Johnson,Merck, Sharpe & Dohme (MSD) and Siemens Healthineers for the research that and development of the implementation framework which is described in this abstract. Chris Melson has not received any direct consultancy fees for any of this work.: The Health Policy Partnership; Financial Interests, Institutional, Full or part-time Employment, The Health Policy Partnership has been commissioned over the past 24 months to conduct non-promotional, non-product related policy projects for: Advanced Accelerator Applications, AEPHCPO (Novartis UAE), Alexion, All.Can International, Amazon Web Services, Amgen, Arythmia Alliance, AstraZeneca, Batten Disease Family Association, Bayer, Bristol Myers Squibb (BMS), Boehringer Ingelheim European Federation of Pharmaceutical Industries and Associations (EFPIA), Elekta, European Society of Anaesthesiology and Intensive Care (ESAIC), GSK, Global Heart Hub (GHH), Guardant Health, Indivior, Initiative Herzklappe e.V, International Cardiomyopathy Network Janssen Pharmaceutica NV, Johnson & Johnson, Life Technologies Europe BV, Medicines for Europe, Medtronic, Merck Sharpe & Dohme (MSD), Neuroendocrine Cancer UK, National Institute for Prevention and Cardiovascular Health (NIPC), Novartis, Novo Nordisk, Philips, Roche Diagnostics, Sanofi, Sophia Genetics, Stemline Therapeutics, Stockholm Institute fo: The Health Policy Partnership.